Stem Cell vs. Prolotherapy: A Patient's Comparative Reading

The conversation around regenerative medicine has, in the last few years, broadened to include prolotherapy alongside the more visible stem cell protocols — and in the Gangnam consult rooms, the comparison is now common enough to require a structured response. The two interventions are routinely grouped under the regenerative-medicine banner; they share the soft-lit consult, the autologous register, and the broad ambition of helping the body do its own remodelling. What they do not share is mechanism, evidence depth, or the kind of patient for whom each is appropriately offered. The closer reading is — as so often in this corner of medicine — more interesting than the brochure register admits. 睇仔細啲先睇到分別, a Hong Kong specialist remarked at a recent Cheongdam consult; she was, on the evidence, correct.

What prolotherapy actually is

Prolotherapy is a regenerative injection protocol that delivers an irritant solution — most commonly hypertonic dextrose, occasionally combined with phenol-glycerol or sodium morrhuate variants — into ligament, tendon, or joint-capsule structures with the aim of provoking a controlled local inflammatory response. The mechanism, on the published reading, is one of induced repair rather than direct cellular contribution. The injected solution creates a low-grade inflammatory cascade that prompts fibroblast proliferation, collagen deposition, and — over a multi-session course — a strengthening of the targeted connective tissue. Patients report an aching localised inflammation for two-to-five days post-injection, a rebound period of stiffness in the first week, and gradual symptomatic improvement over the subsequent six-to-twelve weeks. The protocol is typically administered as a series — three to six sessions at three-to-four-week intervals — rather than as a single intervention. Prolotherapy has accumulated a long and somewhat uneven literature since its codification in the mid-twentieth century, with stronger evidence in chronic ligamentous and tendinous indications and weaker evidence in non-musculoskeletal applications. The 2022 Cochrane review on prolotherapy in chronic musculoskeletal pain concluded that the protocol may help in selected indications, with the evidence strongest for chronic lateral epicondylar tendinopathy, plantar fasciitis, and certain chronic ligamentous instabilities. The cleaner Korean clinics treat prolotherapy as a low-tier regenerative intervention with a defined indication set rather than as a generalised tissue-healing modality. Patients arriving with a longevity-medicine framing are sometimes surprised to find the protocol scoped this narrowly; the surprise is, in my reading, the right kind of surprise to encounter at the consult stage.

What stem cell therapy is — in the regenerative register Korean clinics use

Stem cell therapy in the Korean register refers to a class of protocols delivering mesenchymal stem cells — most commonly adipose-derived, with umbilical-cord-derived protocols available under research frameworks — into the target tissue or systemic circulation. The mechanism is meaningfully different from prolotherapy. Where prolotherapy provokes endogenous repair through controlled inflammation, stem cell therapy delivers cells that themselves participate in the regenerative process — secreting paracrine signalling factors, modulating the local immune environment, and, in indication-appropriate contexts, contributing to tissue remodelling. The cells, in the published literature, do not always engraft permanently; the contribution is more often a sustained signalling effect and an immunomodulatory recalibration than a literal cellular replacement. Studies suggest that mesenchymal stem cell protocols produce structural changes detectable on imaging at the six-to-twelve-month mark in selected indications — moderate-to-advanced knee osteoarthritis being the best-codified application — alongside symptomatic improvements that sometimes parallel and sometimes exceed those produced by lower-tier protocols. The cellular product itself comes in distinguishable forms patients should understand. Stromal vascular fraction (SVF) preserves the heterogeneous cellular population from lipoaspirate enzymatic digestion. Culture-expanded MSCs undergo laboratory passage to enrich the stem-cell fraction. Each variant has a different regulatory footprint, a different manufacturing overhead, and a different evidence base; the [Korean Ministry of Food and Drug Safety](https://www.mfds.go.kr/eng/index.do) maintains the register of approved cellular therapy protocols and gates the offering scope at the indication level. The reading patients should take is that stem cell therapy is not, on the published evidence, a universal regenerative upgrade. It is a higher-tier intervention with a specific evidence base, a specific regulatory register, and a specific cost and recovery profile — and the appropriate use is indication-driven rather than tier-aspirational.

The mechanism gap — provoked repair versus cellular contribution

The cleanest comparative reading frames prolotherapy and stem cell therapy as occupying different mechanistic registers entirely. Prolotherapy operates upstream of the cellular question — the protocol provokes the patient's own repair pathways through a controlled inflammatory stimulus, and the regenerative work is done by tissue already present. Stem cell therapy operates at the cellular level — the protocol introduces cells that themselves participate in the regenerative process, supplementing rather than provoking the endogenous repair machinery. The distinction is not merely academic. The mechanism gap shapes the evidence base, the indication scope, the recovery profile, and the cost differential. Prolotherapy's evidence base is concentrated in chronic ligamentous and tendinous indications where the controlled inflammatory mechanism has a clear physiological rationale. Stem cell therapy's evidence base is concentrated in indications where cellular replacement and immunomodulation contribute meaningfully to the outcome — moderate-to-advanced osteoarthritis, selected autoimmune-adjacent dermatological conditions, and certain non-healing wound contexts. The two protocols do not, in the cleaner clinical reading, compete for the same patient; they address different problems with different mechanisms and produce different kinds of outcomes. A 2021 systematic review in Stem Cell Research and Therapy comparing regenerative interventions across orthopaedic indications found, broadly, that the appropriate comparator for stem cell therapy in moderate osteoarthritis was platelet-rich plasma rather than prolotherapy — and that prolotherapy's appropriate comparator in chronic tendinopathy was not stem cell therapy but conservative physical therapy or, in select cases, PRP. The reading patients should take is that the choice between prolotherapy and stem cell therapy is rarely the choice it appears to be in the marketing register; the actual clinical question is usually whether the indication calls for either, and which lower-cost or comparator intervention may serve as well or better.

Indications — where each protocol is appropriately offered

Prolotherapy's accepted indication set, in the cleaner Korean clinical reading, is comparatively narrow. The protocol is most commonly offered for chronic lateral epicondylar tendinopathy, plantar fasciitis, chronic patellar tendinopathy, and selected ligamentous instabilities — particularly those of the sacroiliac, ankle, and certain knee structures. Less rigorous practices market prolotherapy for a broader range of musculoskeletal complaints; the cleaner clinics gate the indication more carefully and frame the protocol as one of several conservative options rather than as a universal solution. The Mayo Clinic's [overview of regenerative medicine therapies](https://www.mayoclinic.org/) provides a usefully restrained framing of where prolotherapy reads as supported. Stem cell therapy, in the Korean register, is offered for a different and similarly delineated set. Mesenchymal stem cell protocols are most often discussed for moderate-to-advanced knee osteoarthritis, for select dermatological indications under specialist supervision, for certain non-healing wound contexts, and — under research protocols — for selected orthopaedic and longevity-framed applications. The indication overlap between the two protocols is, on closer reading, smaller than the marketing registers suggest. A patient presenting with chronic lateral epicondylar tendinopathy will, in most serious Gangnam practices, be offered conservative management or prolotherapy as first-line options before stem cell therapy is considered — and patients arriving requesting MSC therapy for an indication prolotherapy would competently address are sometimes redirected. A patient presenting with grade-two-to-three knee osteoarthritis, by contrast, will be offered the stem-cell-versus-PRP conversation more directly, with prolotherapy positioned, if at all, as an adjunct rather than as a primary option. Patients should expect indication-specific gating; clinicians offering either protocol for indications outside the published evidence base are, in the cleaner reading, treated as a flag rather than a feature.

Comparison table — prolotherapy versus stem cell, side by side

The categorical comparison below summarises the mechanism, evidence, and protocol differences without ranking the two interventions; the appropriate choice is indication-driven rather than tier-aspirational, and the table is offered in that frame. Note that figures are typical Gangnam protocol ranges drawn from the published medical literature and clinic reporting; individual clinicians and indications vary, and the regulatory register around cellular products in particular is calibrated by indication.

Why patients commonly conflate the two protocols

The conflation, in my reading, traces to three sources. The first is the shared regenerative-medicine banner under which both protocols are marketed — a register that tends to flatten meaningful mechanistic differences into a single tier-aspirational vocabulary. The second is the visual similarity of the consult-room experience: both protocols involve injections, both follow a low-light, hospitality-grade clinic protocol, and both ask the patient for a multi-week recovery commitment. The third source is more particular: a generation of overseas patients arrived at the Gangnam practices with a vocabulary borrowed from longevity-medicine influencer content in which 'regenerative' was used as a single category covering everything from prolotherapy to exosome therapy to umbilical-cord MSC infusion. The clinicians have, in response, become more pedagogical at the consult stage. A first consult at one of the older regenerative practices in Gangnam now routinely begins with a fifteen-to-twenty-minute mechanism explanation that walks the patient through the spectrum — what each tier of intervention does, where each fits in the indication landscape, and what the evidence supports. Patients report finding the explanation reassuring rather than tedious, which suggests the conflation is being read correctly: as a knowledge gap rather than as a marketing failure. The cleaner clinics treat the explanation as part of the protocol; the explanation is, in that frame, the first regenerative intervention. The pedagogical shift has produced a meaningful change in the consent culture. Patients who arrive understanding the mechanism gap make better decisions at the protocol-choice stage and report higher satisfaction at the six-and-twelve-month follow-up windows. The reading from the consultant side is that the conflation is, on balance, costlier in mismatched expectations than in actual treatment-choice errors; patients who chose the wrong protocol relative to their indication tend to surface earlier than the marketing register would predict, and the cleaner clinics build the corrective conversation into the standard work-flow rather than treating it as an exception.

How the Gangnam consult frames the choice between the two

The Gangnam consult, in its current form, frames the prolotherapy-versus-stem-cell decision as a question of indication, evidence depth, and regulatory fit rather than as a tier upgrade. A patient presenting with chronic lateral epicondylar tendinopathy will, in most serious practices, be offered conservative management or prolotherapy as first-line options — three sessions over twelve weeks, with reassessment at six months. A patient presenting with grade-two-to-three knee osteoarthritis and a six-month horizon for symptomatic improvement will be offered the PRP-versus-MSC conversation more directly, with prolotherapy framed, if at all, as an adjunct rather than as a primary option. A patient arriving with a longevity-medicine framing — wanting 'a regenerative protocol' as a wellness intervention rather than as a treatment for a defined indication — will, in the cleaner practices, be redirected toward better-codified protocols and, in some cases, gently declined. The redirection is, in my reading, a feature rather than a bug. The clinics that have built durable international reputations have done so partly by being willing to say no — and the Cantonese phrase the senior clinicians sometimes deploy, 唔啱條件就唔做, captures the disposition cleanly. If the indication does not fit, the procedure is not offered. The standard reads as quietly luxurious in the same way the Cheongdam consult rooms read; the discipline is the protocol. Patients should take from this a less complicated reading than the marketing has produced. Prolotherapy and stem cell therapy are different mechanisms, with different evidence bases, different regulatory frameworks, different recovery profiles, and different appropriate indications. The two are not, as the longevity-vocabulary register has tended to render them, points along a single regenerative spectrum. Patients arriving with that vocabulary internalised should expect the cleaner clinics to slow the consult, lay out the divergence, and gate the protocol on the indication rather than on the marketing tier. The slower consult is, by some distance, the better consult — and the patients who choose accordingly tend to read the clinics that read the protocols correctly as the ones worth the visit. The reading reproduces itself in the satisfaction data; it is, I think, the cleaner pattern.

Frequently asked questions

Is prolotherapy simply a less expensive form of stem cell therapy?

No, and the framing misleads. Prolotherapy provokes the patient's own repair pathways through a controlled inflammatory stimulus; stem cell therapy delivers cells that themselves participate in tissue remodelling and immunomodulation. The two interventions sit on different mechanistic tiers, and the appropriate choice is indication-driven rather than budget-aspirational. A clinician treating prolotherapy and stem cell therapy as interchangeable price points is, in the cleaner Gangnam practices, considered to have misread the protocols.

Can the two protocols be combined in a single treatment plan?

Combination protocols are uncommon but do exist in indication-specific contexts. Some practices offer prolotherapy as a follow-on to a primary stem cell course in selected ligamentous or tendinous indications where the cellular intervention addresses the joint surface and prolotherapy supports the surrounding stabilising structures. The combination is not a default offering, and patients should expect a more elaborate consent process. Studies on combined protocols are limited; the cleaner clinical reading is that combinations be offered for defined indications rather than as a generalised upgrade.

Which protocol has stronger published evidence?

The two evidence bases address different indications, which makes a direct ranking misleading. Prolotherapy has accumulated a long literature in chronic ligamentous and tendinous indications, with the strongest evidence in lateral epicondylar tendinopathy, plantar fasciitis, and selected ligamentous instabilities. Stem cell therapy has a more recent but rapidly expanding literature, particularly in moderate-to-advanced knee osteoarthritis and selected autoimmune-adjacent dermatological conditions. The 2021 Stem Cell Research and Therapy systematic review and the 2022 Cochrane review on prolotherapy together provide a reasonable starting reference.

How do the regulatory frameworks differ in Korea?

Meaningfully so. Prolotherapy is treated as a standard outpatient injection protocol with consent and procedural standards comparable to those for any minor in-clinic intervention. Mesenchymal stem cell protocols sit under the Korean Ministry of Food and Drug Safety's cellular therapy register, with stricter manufacturing, traceability, and consent requirements. Patients can expect a longer pre-procedure work-up, a more formal consent conversation, and, where adipose-derived cells are used, a small lipoaspiration step that prolotherapy does not require.

How long does each protocol take to show results?

Prolotherapy results typically begin to soften symptomatic parameters at four-to-twelve weeks, with the cumulative effect plateauing after a multi-session course at twelve-to-twenty-four weeks. Stem cell protocols show a longer arc — initial symptomatic changes at eight-to-sixteen weeks, with the more substantive structural remodelling readable on imaging at six-to-twelve months. Patients should plan their expectations against the timeline of the chosen mechanism rather than against an idealised composite.

Is the cost differential between the two protocols structural or negotiable?

Structural rather than negotiable. Prolotherapy runs at a routine outpatient injection price point and typically costs ten to twenty-five percent of a comparable mesenchymal stem cell course. The differential reflects the cost of the cellular product, the regulatory overhead, and — for adipose-derived protocols — the lipoaspiration component rather than a tier-aspirational mark-up. Patients should request itemised quotations and compare protocol-against-protocol against the indication being treated rather than against a generic regenerative-medicine register.

Should patients consider prolotherapy as a trial before pursuing stem cell therapy?

In selected indications, yes — and the cleaner Gangnam clinicians sometimes frame it this way explicitly. For chronic ligamentous and tendinous indications where the evidence supports prolotherapy as a first-line option, a course of prolotherapy may produce sufficient symptomatic improvement to remove the case for higher-tier cellular intervention. For indications where prolotherapy lacks supporting evidence, the trial framing does not apply, and the cleaner reading is to pursue the indication-appropriate protocol directly rather than route through a less-supported intervention first.